more_reports

The Latest Psychedelics Articles from Streetwise Reports

Breakthrough Therapy Shows Promising Long-Term Results for Depression

  ()
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging."
Tags: Psychedelics

Showing Results: 1 to 1 of 1